The Indian Pharmaceutical Industry has thrived in the US market by supplying generic pharmaceuticals at competitive prices thanks to the 1984 Drug Price Competition and Patent Term Restoration Act. However, the traditional and conservative strategy is no longer sustainable as we head past the “patent cliff”. An innovative business model characterised by the development of "super-generics," an improved version of an original drug product that has lost patent protection, is the logical next step because it takes less time and money than developing a new chemical entity, while providing higher profit margins and potentially better patient outcomes than generics. This talk will discuss the current market for super-generics, why the traditional Indian pharmaceutical industry should change to become more innovative, and the regulatory, infrastructure, and personnel requirements that such a change would entail. Today, the Indian pharmaceutical business is at a pivotal point, both exciting and challenging. Future growth will be dependent on innovation and technology. Because innovative products have long life cycles and, more significantly, provide product differentiation in a competitive market, the required investments can be recouped, potentially resulting in better profits.
Author(S) Details
Harish K. Jain
Embiotic Laboratories (P) LTD, Mysore Road, Bangalore, India.
View Book:- https://stm.bookpi.org/CAPRD-V3/article/view/4439
No comments:
Post a Comment